HPLC, LC-MS and Peptide Testing: What Each Method Can—and Cannot—Show
The short answer
High-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS) are complementary analytical tools. HPLC can separate components and estimate the relative area of detected peaks under a defined method. Mass spectrometry can measure mass-to-charge signals that support molecular-identity assignments. Neither result, alone, establishes every property of a peptide material.
A useful certificate of analysis therefore states what method was used, what sample was tested, what result was obtained and what the method was designed to demonstrate.
What HPLC measures
In reversed-phase HPLC, components interact differently with a stationary phase and a moving solvent system. They elute at different retention times and are detected, commonly by ultraviolet absorbance. The resulting chromatogram plots detector response against time.
A reported “purity by HPLC” value is generally an area-normalized estimate among peaks detected and integrated under that specific method. It can change with wavelength, gradient, column, sample preparation, integration rules and the response of individual impurities.
What an HPLC purity percentage does not prove
An HPLC area percentage is not automatically a mass fraction of the entire vial. A compound that does not absorb well at the selected wavelength, a volatile component, water, a counter-ion or an impurity that co-elutes with the main peak may not be represented accurately. A large main peak also does not prove that the peak has the claimed molecular identity.
HPLC is powerful when the method has suitable specificity, system suitability and reference comparisons. The number should always be interpreted together with the analytical conditions and other tests.
What mass spectrometry contributes
Mass spectrometry ionizes molecules and measures their mass-to-charge ratios. For peptides, observed ion series can support the expected molecular mass; tandem mass spectrometry can add sequence-related evidence by examining fragment ions. LC-MS first separates sample components and then measures their mass spectra.
A mass signal near an expected value supports identity, but it is not a complete sequence proof in every case. Isomers, some substitutions, adducts, truncations and mixtures can require higher-resolution, tandem or orthogonal analysis.
Why retention time and mass are not interchangeable
Retention time is method-dependent chromatographic behaviour. Molecular mass is a physicochemical measurement derived from ion signals. A matching retention time does not replace mass confirmation, and a matching mass does not show chromatographic purity. Agreement across orthogonal methods is stronger than either observation alone.
Quantity requires another question
Neither normalized chromatographic peak area nor a molecular-ion signal necessarily establishes the total amount of peptide in a container. Quantitative assays require a validated relationship between instrument response and amount, suitable standards and control of sample preparation. Water, salts and counter-ions can contribute to total material mass without being peptide content.
Questions to ask when reading results
Useful questions include: Was the tested sample linked to the stated lot? Was the method described? Was a reference standard used? Were system-suitability criteria met? Does the report distinguish identity, chromatographic purity and quantity? Are representative chromatograms or spectra available?
No analytical report can answer a question that its method was not designed and validated to answer.
Key points
- HPLC separates detected components and can estimate relative chromatographic purity under defined conditions.
- LC-MS adds molecular-mass evidence.
- Identity, purity and quantity are different attributes.
- Sterility and endotoxin require separate tests.
- Orthogonal evidence is more informative than a single headline percentage.
What this article does not establish
This article does not certify any AURAPEP lot, interpret a specific certificate of analysis, or establish that a material is sterile, safe, effective or suitable for human use.
References
- International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures
- International Council for Harmonisation. Q14: Analytical Procedure Development. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development
- U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics
- Molineau J, et al. Effect of dilution solvent and injection volume on peptide chromatographic analysis. J Pharm Biomed Anal. 2022. https://pubmed.ncbi.nlm.nih.gov/36370684/